NexMed Announces First Patent Allowance for Vitaros® in Japan

NexMed, Inc. (Nasdaq: NEXMD), a specialty CRO with a pipeline of product candidates based on the NexACT® technology, today announced that the Japanese Patent Office has issued the Decision to Grant a Patent for NexMed’s patent application entitled, “Prostaglandin Compositions for the Treatment of Male Erectile Dysfunction.” This patent, when issued, will provide Japanese patent protection to September 2021 and is one in a series of patents and pending applications that NexMed owns on Vitaros® and the underlying NexACT technology.

Commenting on today’s news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, “We are very pleased with our first patent allowance for Vitaros in Japan. Throughout its history, the Company has aggressively pursued intellectual property coverage for its technology and products under development. In addition to the newly allowed claims in Japan, we have corresponding coverage and protection for Vitaros in the major international markets.”

About NexMed, Inc.

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.

Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including but not limited to, its ability to obtain and/or enforce patent coverage in major markets.

Nexmed (MM) (NASDAQ:NEXMD)
Historical Stock Chart
From Apr 2024 to May 2024